BioPharmSignal logoBioPharmSignal

Biotech News

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

Oculis (OCS)OculisCompany update

Transaction will enhance Oculis’ strategic flexibility and ownership of Privosegtor while driving long-term value creation Transaction consideration includes $3.8 million up-front cash payment at closing and up to 2,050,000 Oculis ordinary shares subject to lockup release over a period of up to 2

Related news

OCSOculis2026-05-11 20:07 EST

Oculis Reports Q1 2026 Financial Results and Provides Company Update

OCSOculis2026-04-20 08:00 EST

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

LENZLenz Therapeutics Inc2026-06-24 12:30 EST

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

OTLKOutlook2026-08-13 01:45 EST

Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants

LENZLenz Therapeutics Inc2026-08-11 20:05 EST

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

OTLKOutlook2026-05-28 20:00 EST

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LCTXLineage Cell Therapeutics2026-07-30 12:00 EST

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

LCTXLineage Cell Therapeutics2026-05-05 12:00 EST

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

TARSTarsus Pharmaceuticals2026-07-08 20:05 EST

Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

OCGNOcugen2026-05-14 20:30 EST

Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

View all latest news

Oculis

Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...

Recent company news

OCSOculis2026-08-24 08:00 EST

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

OCSOculis2026-08-14 20:05 EST

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

OCSOculis2026-08-10 07:30 EST

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

OCSOculis2026-08-06 20:05 EST

Oculis Reports Q2 2026 Financial Results and Provides Company Update

OCSOculis2026-08-03 08:00 EST

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

Stock data

Close
13.09 USD
Market cap
742.17M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States